Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciro Gallo

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialCesare Gridelli, Fortunato Ciardiello, Ciro Gallo, et al.
Gynecologic Oncology|April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trialsGennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancerMassimo Di Maio, Natasha B Leighl, Ciro Gallo, et al.
Oncotarget|September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACCFrancesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
BMJ Open|October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare systemSilvia Riva, Laura Arenare, Massimo Di Maio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trialsAlessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG StudySandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
The Lancet. Oncology|February 28, 2018
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Ciro Gallo, Michelino De Laurentiis, et al.
The Lancet. Oncology|February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, Domenica Lorusso, Florence Joly, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialCesare Gridelli, Fortunato Ciardiello, Ciro Gallo, et al.
Gynecologic Oncology|April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trialsGennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancerMassimo Di Maio, Natasha B Leighl, Ciro Gallo, et al.
Oncotarget|September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACCFrancesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
BMJ Open|October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare systemSilvia Riva, Laura Arenare, Massimo Di Maio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trialsAlessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG StudySandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
The Lancet. Oncology|February 28, 2018
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Ciro Gallo, Michelino De Laurentiis, et al.
The Lancet. Oncology|February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, Domenica Lorusso, Florence Joly, et al.
Pageof 12